A Phase 3 interventional study of Astragalus and Placebo in High-grade Lymphoma, sponsored by Bnai Zion Medical Center. Not yet recruiting at 1 site in Israel. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-30.
Sponsored by Bnai Zion Medical Center · Phase 3, Interventional, and Prevention
Lymphoma is a malignant disease of the lymph nodes. There are different types of lymphoma: when some of the lymphomas are indolent and require only follow-up, in cases of aggressive lymphoma or indolent lymphoma with a burden of disease, treatment is necessary, which usually includes chemotherapy with or without biological drugs. These drugs often cause significant damage to the quality of life, various symptoms including exhaustion, neuropathic pain, nausea/vomiting, cognitive decline, as well as a drop in blood counts with serious life-threatening infections that cause a delay in the treatment date that may affect the prognosis.
Drug treatments for symptomatic relief and improvement in quality of life in patients with lymphoma are missing, with only a partial effect and involving side effects.
Astragalus (scientific name: Astragalus membranaceus, common name: Huang Qi) is a perennial flowering plant common in China with a long history of use in traditional Chinese medicine. It is given in various forms of root in combination with other herbs, medicinal soups and as tablets, capsules, solutions, ointments for local use, or subcutaneous or intravenous injection. In patients with oncological diseases, a systematic review (4 trials on a total of 342 patients) showed an improvement in nausea and vomiting as well as in the immune system in patients with colon cancer who received Chemotherapy. A meta-analysis of 27 studies on 1,843 patients with colon cancer also demonstrated a reduction in chemotherapy-induced nausea in patients who received a combination of astragalus with chemotherapy compared to chemotherapy alone. In another meta-analysis that included 45 trials on 3,236 patients with liver cancer, an improvement in 12-month survival was reported with products containing astragalus. In a randomized study of 136 patients with lung cancer, three treatment cycles with astragalus by injection in combination with chemotherapy (vinorelbine and cisplatin) resulted in a significant improvement in quality of life compared to the control group that received chemotherapy alone. Similar results found in 23 patients with metastatic malignancy receiving astragalus by injection in combination with chemotherapy. In addition, a study on 90 patients with advanced cancer showed an improvement in fatigue in patients who received astragalus. Also, a pilot study on 60 patients with breast cancer showed that intravenous administration of astragalus improved blood counts in patients who received it in combination with chemotherapy compared to chemotherapy alone. In patients with hematological malignancies, a study was conducted on 498 patients with acute myeloid leukemia and showed that the use of astragalus or plants containing astragalus was associated with improved survival compared to patients who did not receive it. In the context of lymphoma, a pharmacological study in vivo on animals with lymphoma showed that a combination of an astragalus-containing formula with adriamycin-type chemotherapy improved the effect of adriamycin for the treatment of B-cell lymphoma. Another study in patients who had completed conventional chemotherapy with Rituximab Cyclophosphamide Adriamycine Vincristine Prednisone (R-CHOP) for diffuse large B-cell lymphoma showed that administration of a formula containing astragalus improved immune function and blood counts. Finally, a randomized placebo-controlled study showed that giving a formula containing astragalus to patients under R-CHOP chemo-immunotherapy as first line for diffuse large B cell lymphoma high risk significantly reduced the appearance of side effects from the treatment and improved response to the treatment chemotherapy compared to the control group.
Side effects attributed to astragalus include fatigue, weakness, headaches and hypotension, but in the cited studies and meta-analyses, no increase in the rate of side effects was found in the groups of patients who received this plant compared to the control groups, and no safety problems were described in the use of astragalus in combination with chemotherapy.
In light of the multitude of symptoms that affect the quality of life and adherence to treatment in patients with lymphoma receiving chemotherapy, and in light of the encouraging findings in the literature about symptomatic improvement as a result of combining astragalus during chemotherapy in various malignancies, the investigators aim to examine the effectiveness and safety of astragalus during the treatment of patients with high-grade lymphoma on symptomatic relief and adherence to chemotherapy in a randomized, double-blind, placebo-controlled study.
Exclusion Criteria:
Dietary Supplement: Astragalus
Dietary Supplement: Placebo
Patients in the intervention group will receive capsules of the Astragalus plant (scientific name: Astragalus membranaceus, common name: Huang Qi) at an initial dose of 2 grams (4 capsules) per day with the option of increasing the dose to 4 grams (8 capsules) per day according to researchers' assessment and patient tolerance. The dose was determined by a focus group of 5 herbalists and according to data from the literature on oncology patients. The duration of the treatment will be up to a month from the end of the chemotherapy treatment which usually lasts up to six months.
Placebo capsules that look similar to Astragalus capsules will be given to patients from the control group, between 4 and 8 capsules per day according to the researcher's assessment and tolerability. The duration of the treatment will be up to a month from the end of the chemotherapy treatment which usually lasts up to six months.
Quality-of-life
European Organization Research for Treatment of cancer core quality of life (EORTC-QLQ-C30) questionnaire summary score which is calculated from the mean of 13 of the 15 quality-of-life (QLQ-C30) scales of the questionnaire = (Physical Functioning+ Role Functioning+ Social Functioning+ Emotional Functioning+ Cognitive Functioning+ 100-Fatigue+ 100-Pain+ 100-Nausea\_Vomiting+ 100-Dyspnoea+ 100-Sleeping Disturbances+ 100-Appetite Loss+ 100-Constipation+ 100-Diarrhoea)/13. Scores range from minimum 0 to maximum 100; a higher score represents a higher ("better") level of functioning, or a higher ("worse") level of symptoms.
Time frame: From baseline to end-of-treatment, up to 6 months
Symptoms
Measure Yourself Concerns and Wellbeing (MYCAW) questionnaire at end of treatment: two main concerns of the patient which are rated for severity using a simple numerical Likert scale 0-6 (0: not concerning at all; 6: very concerning).
Time frame: From baseline to end-of-treatment, up to 6 months
Fatigue
European Organization Research for Treatment of cancer core quality of life (EORTC-QLQ-C30) questionnaire fatigue score. Scores range from minimum 0 to maximum 100; a higher score represents a higher ("worse") level of fatigue.
Time frame: From baseline to end-of-treatment, up to 6 months
Nausea and vomiting
European Organization Research for Treatment of cancer core quality of life (EORTC-QLQ-C30) questionnaire nausea\&vomiting score. Scores range from minimum 0 to maximum 100; a higher score represents a higher ("worse") level of nausea and vomiting.
Time frame: From baseline to end-of-treatment, up to 6 months
Cognitive function
European Organization Research for Treatment of cancer core quality of life (EORTC-QLQ-C30) questionnaire cognitive functioning score. Scores range from minimum 0 to maximum 100; a higher score represents a higher ("better") level of cognitive functioning.
Time frame: From baseline to end-of-treatment, up to 6 months
Severe neutropenia
Frequency of severe neutropenia episodes defined as absolute neutrophil count under 0.5x10\^9/L
Time frame: Evaluated at day 10-13 of each cycle (each cycle is 14-28 days depending on chemotherapy protocol) during the study treatment (up to 6 months)
Packed cells transfusion
Frequency of packed cells transfusion during the study treatment
Time frame: Through the study treatment, up to 6 months
Use of Granulocyte colony stimulating factors (G-CSF)
Frequency of G-CSF use during the study treatment
Time frame: Through the study treatment, up to 6 months
Infections
Frequency of infections during the study treatment
Time frame: Through the study treatment, up to 6 months
Hospitalizations
Frequency of hospitalizations during the study treatment
Time frame: Through the study treatment, up to 6 months
Compliance to chemotherapy
Relative dose intensity (RDI) which is the ratio of delivered dose intensity (DDI) of chemotherapy with standard dose intensity (SDI) of chemotherapy = DDI/SDI
Time frame: Through the study treatment, up to 6 months
Overall response rate (ORR)
Percentage of patients who have a partial response or complete response to the treatment of lymphoma
Time frame: Through the study treatment, up to 6 months
Complete response (CR) rate
Percentage of patients who have a complete response to the treatment of lymphoma
Time frame: Through the study treatment, up to 6 months
Progression-free survival (PFS)
The length of time during and after the treatment of lymphoma (first line) that patient lives and disease does not progress
Time frame: Up to 2 years after end-of-study treatment: up to 2.5 years
Overall survival (OS)
The length of time during and after the treatment of lymphoma (first line) that patient lives
Time frame: Up to 2 years after end-of-study treatment: up to 2.5 years
Incidence of Treatment-Emergent Adverse Events
According to report of adverse events, severe adverse events, drug interactions
Time frame: Through the study treatment, up to 6 months
Economic analysis
Calculation of quality-adjusted life years based on EuroQol-5 Dimension (EQ-5D) scale. The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The patient indicates health state by ticking the box next to the most appropriate statement in each of the five dimensions. This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state. The EQ visual analogue scale (VAS) records the patient's self-rated health on a vertical visual analogue scale, where the endpoints are labelled 'The best health you can imagine' and 'The worst health you can imagine'. The VAS can be used as a quantitative measure of health outcome that reflect the patient's own judgement.
Time frame: Through the study treatment, up to 6 months
Documents are hosted by the registry — open the source record to download them.
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Bnai Zion Medical Center